$0.1870
-0.0133-6.64%
Last update: Nov 10, 7:29 PM
Context Therapeutics Inc
CNTXNASDAQ
Context Therapeutics fell 83.2% from $1.19 to $0.20, behind the S&P 500's +9.8%. Its worst day was Jun 15 (−51.1%), and its low came Nov 5 at $0.19.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Context Therapeutics closed at its highest level of the year, 182.4% above where the year started.
+8.7% · S&P 500 −0.6%
EPS of $-0.14 missed the $-0.11 estimate on $0.00 revenue (est. $-1.5M).
Story events cover the past 12 months · Times ET
+5.3% · S&P 500 −0.3%
EPS of $-0.09 beat the $-0.12 estimate on $0.00 revenue.
−3.3% · S&P 500 −0.3%
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapyCytokine Release Syndrome ("CRS") in…
−51.1%, the year's worst day, on 21M shares, the year's heaviest volume · S&P 500 +1.8%
EPS of $-0.15 missed the $-0.09 estimate on $0.00 revenue.
−27.3% · S&P 500 −0.2%
Where it ended: a close of $0.20 on Nov 9, 2026.
Nothing in the past 12 months.
All CNTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CNTX and SPY from Benzinga historical bars. Not investment advice.
